BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Impulse Dynamics and MetaCure Sign Asia-Pacific Distribution Agreements With Vitality Devices


2/21/2012 10:49:02 AM

February 21, 2012 -- Medical device companies Impulse Dynamics NV and MetaCure Ltd. have announced today the signing of a strategic Asia-Pacific distribution agreement with newly formed Australian company Vitality Devices Pty. Ltd. Under this agreement Vitality will distribute Impulse Dynamics’ OPTIMIZER System for treating Chronic Heart Failure (CHF) and MetaCure’s DIAMOND System for treating Type 2 Diabetes and associated metabolic diseases. Distribution of both medical devices will be in Australia, Singapore, Taiwan, South Korea, the Philippines, New Zealand, Indonesia, Malaysia, Thailand, Vietnam, Cambodia, Laos and the United Arab Emirates.

Vitality was established by Australian biotechnology entrepreneurs Dr. Greg Collier and Dr. James Campbell, who previously served as the executive management team of the drug development company ChemGenex Pharmaceuticals from 2002, guiding its growth, clinical development and ultimate sale to Cephalon Inc. in 2011. Vitality will specialize in commercializing medical technology in the Asia Pacific region; it will focus on the Impulse Dynamics and MetaCure implants as the cornerstone of its commercial platform, adding additional medical devices over time.

“We view our partnership agreement with Vitality as a strategic asset,” said Impulse Dynamics and MetaCure CEO, Dr. Irit Yaniv. “With the growing incidence of Chronic Heart Failure and Metabolic Disease throughout the Asia Pacific region, we view these markets as a primary commercial target and source of growth for our companies”.

Impulse Dynamic’s Optimizer III and MetaCure’s Diamond System represent technological advancement in device based disease treatment. The Optimizer III implant uses Cardiac Contractility Modulation (CCM) treatment to improve exercise tolerance and quality of life in CHF patients. The DIAMOND System is an implantable electrical stimulator for improving blood glucose levels and metabolic parameters in patients suffering from diabesity.

“We are excited about the opportunity to introduce novel, state of the art medical technologies such as the OPTIMIZER III and DIAMOND System to patients in the region” said Dr. Greg Collier, Managing Director of Vitality. “We believe that these technologies will improve available treatment and quality of care for heart failure and metabolic patients throughout these territories”.

About Impulse Dynamics - Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure. The Optimizer III with Cardiac Contractility Modulation (CCM) therapy is CE marked and is available in select excellence centers across Europe and Asia.

About MetaCure – MetaCure is a medical device company dedicated to developing innovative minimally invasive Interventional Diabetology solutions for Type 2 Diabetes and its metabolic comorbidities. The Company’s leading product, The DIAMOND System has been shown to significantly improve glycemic and metabolic control while maintaining a clean safety profile. The DIAMOND System is CE approved since 2007 and is commercially available in selected excellence centers in Europe.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES